Erasca receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Erasca Inc (ERAS)
Erasca Inc stock price live, this page displays NASDAQ ERAS stock exchange data. View the ERAS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Erasca Inc real time stock price chart below.
What Is the Erasca Inc Stock Price Today?
The Erasca Inc stock price today is 1.460.
What Is the Stock Symbol for Erasca Inc?
The stock symbol for Erasca Inc is ""ERAS.""
What Stock Exchange Does Erasca Inc Trade On?
Erasca Inc is listed and trades on the NASDAQ stock exchange.
Is Erasca Inc a Good Stock to Buy?
Determining whether Erasca Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ERAS quote. (ISIN: US29479A1088)
What Is the Erasca Inc Stock Price Today?
The Erasca Inc stock price today is 1.460.
What Is the Stock Symbol for Erasca Inc?
The stock symbol for Erasca Inc is ""ERAS.""
What Stock Exchange Does Erasca Inc Trade On?
Erasca Inc is listed and trades on the NASDAQ stock exchange.
Is Erasca Inc a Good Stock to Buy?
Determining whether Erasca Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ERAS quote. (ISIN: US29479A1088)
NASDAQ
Currency in USD
1.460
+0.030(+2.10%)
Closed·
After Hours
1.480+0.020(+1.37%)
·
Fair Value
An estimate of a Erasca's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.411
1.475
52 wk Range
1.010
3.305
ERAS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ERAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Erasca's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4111.475
52 wk Range
1.0103.305
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ERAS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Erasca's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
5.286
Upside
+262.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Erasca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Erasca Inc For: 26 June
- Investing.com
- FDA clears Erasca’s new cancer drug applications
- Investing.com
- Erasca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Erasca Inc For: 26 June
- Investing.com
- FDA clears Erasca’s new cancer drug applications
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Erasca Inc Company Profile
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company’s products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Compare ERAS to Peers and Sector
Metrics to compare | ERAS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipERASPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −3.4x | −0.5x | |
PEG Ratio | −0.09 | 0.00 | 0.00 | |
Price/Book | 1.0x | 2.7x | 2.6x | |
Price / LTM Sales | - | 151.9x | 3.3x | |
Upside (Analyst Target) | 179.7% | 194.7% | 43.4% | |
Fair Value Upside | Unlock | 3.8% | 7.1% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.286
(+262.03% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-- / -0.1172
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Erasca Trade On?
Erasca is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Erasca?
The stock symbol for Erasca is "ERAS."
What Is the Erasca Market Cap?
As of today, Erasca market cap is 415.02M.
What Is Erasca's Earnings Per Share (TTM)?
The Erasca EPS (TTM) is -0.59.
When Is the Next Erasca Earnings Date?
Erasca will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is ERAS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Erasca Stock Split?
Erasca has split 0 times.
How Many Employees Does Erasca Have?
Erasca has 103 employees.
What is the current trading status of Erasca (ERAS)?
As of 08 Aug 2025, Erasca (ERAS) is trading at a price of 1.46, with a previous close of 1.43. The stock has fluctuated within a day range of 1.41 to 1.48, while its 52-week range spans from 1.01 to 3.31.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.